OncoSec Medical (NASDAQ:ONCS) Earns Buy Rating from HC Wainwright

OncoSec Medical (NASDAQ:ONCS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Thursday, November 9th. They presently have a $6.00 target price on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 179.07% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Maxim Group reiterated a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $5.33.

OncoSec Medical (NASDAQ:ONCS) opened at $2.15 on Thursday. OncoSec Medical has a 52 week low of $0.88 and a 52 week high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). equities research analysts anticipate that OncoSec Medical will post -0.86 earnings per share for the current fiscal year.

WARNING: This piece was originally reported by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/hc-wainwright-reaffirms-buy-rating-for-oncosec-medical-incorporated-oncs/1771926.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.